AbbVie Acquires Gilgamesh Pharma's Depression Drug for Up to $1.2 Billion
ByAinvest
Monday, Aug 25, 2025 9:14 am ET1min read
ABBV--
Deal Details
Under the terms of the agreement, AbbVie will acquire Gilgamesh's lead investigational candidate, bretisilocin (GM-2505), a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser, currently in Phase 2 development for the treatment of major depressive disorder (MDD). The deal also includes an option-to-license agreement that remains in effect and will be transferred to Gilgamesh Pharma Inc., a new entity that will hold Gilgamesh's employees and other programs [1].
Strategic Significance
The acquisition underscores AbbVie's commitment to broadening and enhancing psychiatric care by investing in novel treatment approaches. "The field of psychiatry represents one of the most challenging areas in medicine, with a significant need for innovative solutions," said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "This acquisition underscores our commitment to broadening and enhancing psychiatric care by investing in novel treatment approaches with the potential to reach patients for whom other treatments have been ineffective. We look forward to advancing bretisilocin to late-stage clinical development" [1].
Market Impact
The acquisition is seen as a strategic move by AbbVie to strengthen its position in the psychiatric drug market. Psychedelic compounds, including 5-HT2A receptor agonists, have gained recognition as potential treatments for mental health disorders, such as MDD, because of their demonstrated rapid, robust, and durable antidepressant effects. However, existing agents in this class are hampered by their long duration of psychoactive experience [1].
Financial Implications
The acquisition is subject to customary closing conditions. The deal is expected to expand AbbVie's portfolio of treatments for depression and other psychiatric disorders, positioning the company to capture a larger share of the market. The transaction is seen as a significant investment in the company's future growth and market expansion.
References
[1] https://news.abbvie.com/2025-08-25-AbbVie-to-Acquire-Gilgamesh-Pharmaceuticals-Bretisilocin,-a-Novel,-Investigational-Therapy-for-Major-Depressive-Disorder,-Expanding-Psychiatry-Pipeline
[2] https://www.prnewswire.com/news-releases/abbvie-to-acquire-gilgamesh-pharmaceuticals-bretisilocin-a-novel-investigational-therapy-for-major-depressive-disorder-expanding-psychiatry-pipeline-302537266.html
AbbVie has agreed to acquire Gilgamesh Pharma's depression drug for up to $1.2 billion. The deal is expected to expand AbbVie's portfolio of treatments for depression and other psychiatric disorders. AbbVie's products are focused on treating various diseases, with net sales distributed across multiple countries. The acquisition is seen as a strategic move by AbbVie to strengthen its position in the psychiatric drug market.
North Chicago, Ill. and New York, Aug. 25, 2025 - AbbVie Inc. (NYSE: ABBV) has agreed to acquire Gilgamesh Pharmaceuticals Inc. (Gilgamesh) for up to $1.2 billion, including an upfront payment and development milestones. The acquisition is expected to expand AbbVie's portfolio of treatments for depression and other psychiatric disorders.Deal Details
Under the terms of the agreement, AbbVie will acquire Gilgamesh's lead investigational candidate, bretisilocin (GM-2505), a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser, currently in Phase 2 development for the treatment of major depressive disorder (MDD). The deal also includes an option-to-license agreement that remains in effect and will be transferred to Gilgamesh Pharma Inc., a new entity that will hold Gilgamesh's employees and other programs [1].
Strategic Significance
The acquisition underscores AbbVie's commitment to broadening and enhancing psychiatric care by investing in novel treatment approaches. "The field of psychiatry represents one of the most challenging areas in medicine, with a significant need for innovative solutions," said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "This acquisition underscores our commitment to broadening and enhancing psychiatric care by investing in novel treatment approaches with the potential to reach patients for whom other treatments have been ineffective. We look forward to advancing bretisilocin to late-stage clinical development" [1].
Market Impact
The acquisition is seen as a strategic move by AbbVie to strengthen its position in the psychiatric drug market. Psychedelic compounds, including 5-HT2A receptor agonists, have gained recognition as potential treatments for mental health disorders, such as MDD, because of their demonstrated rapid, robust, and durable antidepressant effects. However, existing agents in this class are hampered by their long duration of psychoactive experience [1].
Financial Implications
The acquisition is subject to customary closing conditions. The deal is expected to expand AbbVie's portfolio of treatments for depression and other psychiatric disorders, positioning the company to capture a larger share of the market. The transaction is seen as a significant investment in the company's future growth and market expansion.
References
[1] https://news.abbvie.com/2025-08-25-AbbVie-to-Acquire-Gilgamesh-Pharmaceuticals-Bretisilocin,-a-Novel,-Investigational-Therapy-for-Major-Depressive-Disorder,-Expanding-Psychiatry-Pipeline
[2] https://www.prnewswire.com/news-releases/abbvie-to-acquire-gilgamesh-pharmaceuticals-bretisilocin-a-novel-investigational-therapy-for-major-depressive-disorder-expanding-psychiatry-pipeline-302537266.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet